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Abstract
Background: Previous meta-analyses regarding the performance of interferon-gamma release assays (IGRAs) for
tuberculosis diagnosis in children yielded contrasting results, probably due to different inclusion/exclusion criteria.
Methods: We systematically searched PubMed, EMBASE and Cochrane databases and calculated pooled estimates
of sensitivities and specificities of QuantiFERON-TB Gold In Tube (QFT-G-IT), T-SPOT.TB, and tuberculin skin test
(TST). Several sub-analysis were performed: stratification by background (low income vs. high income countries);
including only microbiological confirmed TB cases; including only studies performing a simultaneous three-way
comparison of the three tests, and including immunocompromised children.
Results: Overall, 31 studies (6183 children) for QFT-G-IT, 14 studies (2518 children) for T-SPOT.TB and 34 studies
(6439 children) for TST were included in the analyses. In high income countries QFT-G-IT sensitivity was 0.79 (95%
IC: 0.75-0.82) considering all the studies, 0.78 (95%CI:0.70-0.84) including only studies performing a simultaneous
three-way comparison and 0.86 (95%IC 0.81-0.90) considering only microbiologically confirmed studies. In the same
analyses T-SPOT.TB sensitivity was 0.67 (95%IC 0.62-0.73); 0.76 (95%CI: 0.68 to 0.83); and 0.79 (95%IC 0.69-0.87),
respectively. In low income countries QFT-G-IT pooled sensitivity was significantly lower: 0.57 (95%IC:0.52-0.61),
considering all the studies, and 0.66 (95%IC 0.55-0.76) considering only microbiologically confirmed cases; while
T-SPOT.TB sensitivity was 0.61 (95%IC 0.57-0.65) overall, but reached 0.80 (95%IC 0.73-0.86) in microbiologically
confirmed cases. In microbiologically confirmed cases TST sensitivity was similar: 0.86 (95%IC 0.79-0.91) in high
income countries, and 0.74 (95%IC 0.68-0.80) in low income countries. Higher IGRAs specificity with respect to TST
was observed in high income countries (97-98% vs. 92%) but not in low income countries (85-93% vs. 90%).
Conclusions: Both IGRAs showed no better performance than TST in low income countries.
Background
Diagnosis of paediatric tuberculosis infection remains a
challenging issue. Tuberculin skin test (TST) has several
limitations: sensitivity may be influenced by the child’s
age and immunologic status, bacille Calmette-Guérin
(BCG) vaccination or non-tuberculosis mycobacterium-
infections; in case of repeated tests a booster effect can
occur and a double access to a health care facility is
needed. Nevertheless, infiltrate measurement may be
operator-dependent [1-4]. Interferon gamma release
assays (IGRAs), including the commercially available
assays QuantiFERON®-TB Gold (QFT-G; Cellestis,
Australia), QuantiFERON®-TB Gold In-Tube (QTF-G-
IT, Cellestis, Australia), and the T-SPOT TB (T-SPOT®,
Oxford Immunotec Ltd. UK), have been extensively used
for the diagnosis of tuberculosis infection in adults.
IGRAs allow detection of circulating T-cells responsive
to specific Mycobacterium tuberculosis antigens, which are
absent in BCG and many non-tuberculosis mycobacteria,
and displayed similar sensitivity and higher specificity than
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TST in adults (table 1) [5-12]. However, IGRA perfor-
mance in paediatric populations is still under debate and
caution is recommended for their use and interpretation
in children [13]. Some authors reported a sub-optimal
IGRA sensitivity in children [14], but this finding has not
been confirmed by others [8]. Five meta-analyses have pre-
viously assessed IGRA sensitivity and specificity in chil-
dren but reported pooled estimates largely differ (Table 1)
[1,5,9-11]. Such discordances may be due to different
inclusion/exclusion criteria and, thus, different characteris-
tics of the study populations (i.e. proportion of immuno-
compromised/HIV infected and/or young children
included). The setting is also relevant. IGRA performance
is influenced by the child’s immunologic status, which, in
turn, may be impaired by several conditions commonly
observed in low income countries, such as malnutrition,
HIV-infection, and elminthiasis [1-3]. Hereby, we report
results of an updated meta-analysis regarding IGRA per-
formance in children, focusing on settings, age, and immu-
nologic status of the study children.
Methods
A literature search using multiple keywords and standar-
dized terminology in Medline, EMBASE and Cochrane
databases dating back to their inception up to and through
June 7th, 2013, as summarized in Additional file 1,
appendix 1. Inclusion and exclusion criteria, extraction of
data and assessment of study quality are reported in Addi-
tional file 1. In particular only studies evaluating Quanti-
FERON®-TB Gold In-Tube (QTF-G-IT, Cellestis,
Australia), and/or T-SPOT TB (T-SPOT®, Oxford Immu-
notec Ltd. UK) in comparison to TST were included while
studies using QFT-G were excluded.
Statistical methods
For each included study, we computed and calculated sen-
sitivity or specificity (and 95% CIs) and summarized the
results in forest plots. Random-effects meta-analysis was
performed using MetaDiSc®, Meta-analysis of Diagnostic
and Screening tests, Version 1.4 [15]. Studies were
weighted by total sample size to pool estimates of sensitiv-
ity and specificity across the studies. Chi-square test was
used to evaluate the presence of statistically significant het-
erogeneity across studies, whose variance proportion attri-
butable to between studies heterogeneity was expressed
calculating the I2 statistic.
Results
For the analysis of sensitivity, 31 studies (20 conducted in
high income countries and 11 in low income countries) for
QFT-G-IT, including 6183 children [3,16-44], 14 studies
(9 conducted in high income countries and 5 conducted
in low income countries for T-SPOT.TB including
2518 children [10,14,16,18,19,22,23,37,39,45-48,50] and
Table 1 Sensitivity and specificity of Interferon-gamma release assays (IGRAs) and tuberculin skin test (TST) in the
previous published meta-analyses [1,5-12]
TST QFN-G-IT T-SPOT.TB Population Number of
studies
considered
Author, year of
publication
Sensitivity 0.70 (95%CI 0.67-0.72) 0.81 (95%CI 0.78-0.89) 0.84 (95%CI 0.81-0.87) Adults 124 Diel, 2010
0.77 (95%CI 0.71-0.82) 0.78 (95% CI 73-82) 0.90 (95%CI 0.86-0.93) Adults 20 Pai, 2008
0.80 (95%CI 0.75-0.91) 0.81 (95CI 0.78-0.84) Adults 27 Sester, 2010
0.80 (95%CI 0.70-0.90) 0.83(95%CI 0.75-0.92) 0.84(95%CI 0.63-1.00) Children 32 Mandalakas, 2011
0.71(95%CI 0.67-0.75) 0.70 (95%CI 0.65-0.75) 0.62 (95%CI 0.57-0.67) Children 16 Sun, 2011
0.82(95%CI 0.72-0.93) 0.79 (95%CI 0.70-0.89) 0.74 (95%CI 0.59-0.90) Children 11 Chiappini, 2012
0.77 (95%CI 0.64-0.73) Adults and
Children
11 Dheda, 2009
0.66 (95%IC 0.53-0.78) Children 6 Machingaidze, 2011
0.71 (95%CI 0.65-0.74) 0.76 (95%CI 0.70-0.83) 0.88 (95%CI 0.81-0.95) Adults and
Children
58 Menzies, 2007
Specificity 0.99 (95%CI 0.98-1.00) 0.86 (95%CI 0.81-0.90) Adults 124 Diel, 2010
0.59 (95%CI 0.46-0.73) 0.96 (95%CI 94-98) 0.93 (95%CI 0.86-1.00) Adults 20 Pai, 2008
0.82 (95%CI 0.70-0.91) 0.82 (95%CI 0.78-0.86) Adults 27 Sester, 2010
0.85 (95%CI 0.69-1.00) 0.91 (95% CI 0.78-1.00) 0.94 (95%CI 0.87-1.00) Children 32 Mandalakas, 2011
0.56 (95% CI 0.50-0.61) 1.00 (95%CI 0.84-1.00) 0.90 (95%CI 0.86-0.93) Children 16 Sun, 2011
0.83 (95%CI 0.74-0.92) 0.95 (95%CI 0.93-0.97) 0.96 (95%CI 0.95-1.00) Children 8 Chiappini, 2012
0.66 (95%CI 0.46-0.86) 0.97 (95%CI 0.96-0.99) 0.92 (95%CI 0.86-0.99) Adults and
Children
58 Menzies, 2007
Sollai et al. BMC Infectious Diseases 2014, 14(Suppl 1):S6
http://www.biomedcentral.com/1471-2334/14/S1/S6
Page 2 of 11
34 studies (18 studies conducted in high income countries
and 16 studies conducted in low income countries) for
TST including 6439 children [14,17-35,37-43,45-47,49,50]
were included.
The specificity analysis included 17 studies, overall
including 3844 children (11 conducted in high income
countries and 6 in low income countries) using QFT-G-IT
[16-22,24-27,30,32,34,37,43], 9 studies overall including
1296 children (6 conducted in high income countries and
3 in low income countries) using T-SPOT.TB [16,18,19,
22,23,45,46,48,49], and 17 studies overall including 3548
children (10 conducted in high income countries and
7 conducted in low income countries) using TST [17-23,
25-27,30,32,34,37,45-47], as summarized in Figure 1.
Pooled IGRAs and TST sensitivity and specificity
in high and low income countries
Considering the whole study population, significantly
higher sensitivities of QFT-G-IT and TST in high- than in
low-income countries were observed, with no difference
between them, while T-SPOT.TB sensitivity was particu-
larly low in both settings (0.67 [95%IC 0.62-0.73] in high
income countries, and 0.61 [95%IC 0.57-0.65] in low
income countries) (Figures 1, 2, 3, 4, 5, 6).
In particular, QFT-G-IT sensitivity was 0.79 (95%IC:
0.75-0.82) in high income countries, and 0.57 (95%IC
0.52-0.61) in low income countries, and TST pooled sensi-
tivity was 0.78 (95%IC 0.74-0.82) in high income countries,
and 0.67 (95%IC 0.64-0.70) in low income countries.
Specificity of the three test was similar in low income
countries while both QFT-G-IT and T-SPOT.TB displayed
higher specificity than TST in high income countries.
In particular, QFT-G-IT specificity was 0.97 (95%IC 0.96-
0.98) in high income countries, and 0.85 (95%IC 0.82-0.88)
in low income countries. T-SPOT.TB pooled specificity
was 0.98 (95%IC 0.96-0.99) in high income countries,
and 0.93 (95%IC 0.87-0.96) in low income countries. TST
specificity was 0.92 (95%IC 0.89-0.93) in high income coun-
tries, and 0.90 (95%IC 0.87-0.92) in low income countries.
Sub-analysis for sensitivity including only
microbiologically confirmed cases
Data regarding microbiologically confirmed cases were
available in 16 studies (11 studies conducted in high
income countries and 5 studies conducted in low income
countries), overall including 3689 children for QFT-G-T
[3,14,17,19,20,22,24,26-29,32,34,37,40,44], 9 studies (4 con-
ducted in high income countries and 5 conducted in low
income countries), including 2013 children for T-SPOT.
TB [14,19,22,45-50], and 17 studies (10 studies conducted
in high income countries and 7 studies conducted in low
income countries), including 4494 children for TST
[3,14,17,19,20,22,24,26,29,32,37,40,45,47,49,50].
In this analysis sensitivity of the three test was similar
(0.81 (95%CI: 0.76-0.85) for QFT-G-IT, 0.80 (95%CI: 0.74-
0.84) for T-SPOT.TB, and 0.79 (95%CI: 0.75-0.83) for TST.
A sub-analysis in studies conducted in high income and
low income countries was performed. In high income
countries sensitivity of the three test was confirmed to be
similar but IGRAs performance in low income countries
was suboptimal. QFT-G-IT pooled sensitivity was 0.86
(95%IC: 0.81-0.90) in high income countries but only
0.66 (95%IC: 0.55-0.76) in low income countries. Even
when excluding studies including HIV-infected children,
QFT-G-IT pooled sensitivity in low income countries
reached only 0.68 (95%IC: 0.55-0.76).
T-SPOT.TB pooled sensitivity was 0.79 (95%IC: 0.69-
0.87) in high income countries, and 0.80 (95%IC 0.73-0.86)
in low income countries. TST sensitivity was 0.86 (95%IC
0.79-0.91) in high income countries, and 0.74 (95%IC 0.68-
0.80) in low income countries (table 2).
Sub-analysis conducted including only studies
performing a simultaneous three-way comparison
in the same children (QFT-G-IT; T-SPOT.TB; TST)
Six of the available studies, including 618 children, evalu-
ated all three tests simultaneously in the same children
[18,19,22,23,37,39]. All these studies were performed in
high income countries. The meta-analytic estimate for
sensitivity was 0.78 (95%CI: 0.70-0.84) for QFT-G-IT;
0.76 (95%CI: 0.68-0.83) for T-SPOT.TB, and 0.85 (95%CI:
0.78-0.91) for TST. The meta-analytic estimate for specifi-
city was 0.97 (95%CI: 0.93-0.99) for QFT-G-IT, 0.97 (95%
CI: 0.93-0.99) for T-SPOT.TB, and 0.84 (95%CI: 0.79-0.89)
for TST (table 2).
Sub-analysis in immunocompromised/HIV-infected
children populations
Overall, 11 studies have assessed utility of IGRAs in
paediatric populations including HIV infected children
[3,34,43,50,52-58]. However, three of them were excluded
because the used tests were the in house-ELISPOT
[52,55] and the QFT-G not in-tube assay [58]. In five stu-
dies utility of IGRAs in immunocompromised children
was evaluated as a screening for LTBI with no case of
active TB disease included [53-57], and concordance
between tests was evaluated. All the results suggest that
due to high rates of discordant and indeterminate results
in this population, IGRAs should be interpreted with
caution and represent tools of little help for TB infection
management for immune-compromised children both in
high- and low- prevalence settings [53-57].
Complete data for a specific subgroup-analysis were
available in four studies [3,34,43,50]. Haustein and col-
leagues included in their analysis immunocompromised
children with several different pathologic conditions,
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including malignancies [3]. In three studies utility of
QFT-G-IT was compared to TST [3,34,43], while Ling
and colleagues compared T-SPOT.TB to TST [50].
The meta-analytic estimate for sensitivity was very low
and similar for QFT-G-IT and T.SPOT.TB: 0.47 (95%CI:
0.38-0.55) for QFT-G-IT and 0.54 (95%CI:0.49-0.59) for
TST. The meta-analytic estimate for specificity was not
performed since only data from 2 studies were available
[34,43]. Meta-analytic estimate for sensitivity and specificity
for T-SPOT.TB was not performed due to lack of data. In
the only study available, Ling and colleagues assessed the
incremental value of T-SPOT.TB over and above patient
characteristics and conventional tests in 491 smear-nega-
tive children from two hospitals in Cape Town, South
Africa, founding that cough longer than 2 weeks, fever
longer than 2 weeks, night sweats, malaise, history of
household contact and HIV status were the most impor-
tant predictors of culture-confirmed TB and concluding
that T-SPOT.TB did not have added value beyond clinical
data and conventional tests for diagnosis of TB disease in
smear-negative children in a high-burden setting [50].
Studies with children populations aged ≤ 5 years
Six studies, including 1733 children, included exclusively
children aged ≤ 5 years [19,28,30,42,59,60]. In particular,
Detjen and colleagues evaluated in 2007 the diagnostic
accuracy of TST and 2 IGRAs in a cohort of 73 children
(median age: 39 months); comparing 28 children with bac-
teriologically confirmed TB with children without TB (23
with bacteriologically confirmed non-tuberculous myco-
bacterial lymphadenitis and 22 with other non-mycobac-
terial respiratory tract infections) [19]. Specificity of QFT-
Figure 1 Selection of studies for the meta-analysis. *Inclusion/exclusion criteria as reported in the text and in additional file 1.
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IT for TB was 1.00 (95%CI: 0.91-1.00), and the specificity
of T-SPOT was 0.98 (95% CI: 0.87-1.00). Specificity of
TST resulted considerably lower (0.58; 95% CI: 0.42-0.73).
The specificity of TST was 0.10 (95% CI: 0.1–0.33) in chil-
dren with nontuberculous mycobacterial lymphadenitis
and 1.00 (95% CI: 0.83–1.00) in children with other non-
mycobacterial respiratory tract infections. The sensitivity
of both QFT-IT and T-SPOT was 0.93 (95% CI: 0.77–
0.99), and the sensitivity of TST was 1.00 (95% CI: 0.88–
1.00). Agreement between the two IGRAs was 95.6%
(k=0.91). The authors concluded that IGRAs showed high
diagnostic value in bacteriologically confirmed childhood
TB and when performed in addition to TST they could be
able to distinguish -positive TST results caused by non-
tuberculous mycobacterial disease [19]. In the same year,
Okada and colleagues compared test results of QFT-G-IT
and TST in 195 young children household contacts of pul-
monary TB patients in Cambodia, founding considerable
agreement (k=0.63) between the two tests and that results
were not affected by BCG vaccination in a logistic
Figure 2 Forest plot of sensitivity of QuantiFERON-TB Gold In Tube (QFT-G-IT) in low-income countries. The squares are single study
estimates and the error bars represent the 95% confidence intervals (95% CIs). The diamonds are pooled estimates.
Figure 3 Forest plot of sensitivity of QuantiFERON-TB Gold In Tube (QFT-G-IT) in high-income countries. The squares are single study
estimates and the error bars represent the 95% confidence intervals (95% CIs). The diamonds are pooled estimates.
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regression analysis [42]. The authors suggested QFT-G-IT
may be a substitute for TST in detecting latent TB infec-
tion in childhood contacts aged ≤5 years, especially in
those who may have a false-positive TST due to BCG vac-
cination or non-tuberculous mycobacterial infection [42].
Debord and colleagues evaluated QFT-G-IT perfor-
mance restrospectively in 19 French immunocompetent
children (median age: 1.52 years) with active tuberculosis
[28]. The rate of indeterminate results was 0/19 and the
rates of positivity were 6/10 and 9/9 in <2 and 2- to 5-
year-old children, suggesting QFT-G-IT could be a useful
tool to improve diagnosis of tuberculosis in association to
TST even in young children [29]. In the study conducted
by Moyo and colleagues including 397 South African chil-
dren aged less than 3 years, QFT-G-IT and TST showed
notable agreement (k=0.79), however, both tests had low
sensitivity for TB disease (38% and 35%) [30]. On contrast,
Pavic and colleagues found in 142 Croatian children aged
<5 years significant discordance between QFT-G-IT and
TST (k=0.59), concluding that both tests should be
performed in high-risk children aged <5 years, considering
the child infected if either or both tests are positive [59].
Nkurunungi and colleagues found in their cross-sectional
study conducted on 907 children screened for LTBI in a
high prevalence African setting that T-SPOT.TB results
were unstable over a three-week follow-up interval, and
that TST compares poorly with T-SPOT.TB, making the
categorisation of children as TB-infected or TB-uninfected
difficult [60].
Although, in general, results in young children were
encouraging, a specific meta-analysis for this subjects,
could not be performed as complete data were not avail-
able in most studies, except for Detjen et al. ‘s study [19].
Discussion
Data on IGRAs’ performance in children are accumulat-
ing. In previous meta-analyses, similarly to data reported
in adults, higher IGRA specificity with respect to TST has
been reported. However, the reported IGRA sensitivity
ranged between 62% and 89% for T-SPOT.TB and 66%
Figure 4 Forest plot of sensitivity of T-SPOT.TB in low-income countries. The squares are single study estimates and the error bars
represent the 95% confidence intervals (95% CIs). The diamonds are pooled estimates.
Figure 5 Forest plot of sensitivity of T-SPOT.TB in high-income countries. The squares are single study estimates and the error bars
represent the 95% confidence intervals (95% CIs). The diamonds are pooled estimates.
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and 83% for QFT-G-IT [1,5,9-11]. Differences between
IGRA performance in low income and high income coun-
tries were evaluated only in one meta-analysis which con-
sidered only QFT-G-IT- (and not T-SPOT.TB-) based
studies [1]. In that analysis, significantly lower QFT-G-IT
sensitivity was observed in high-burden TB settings com-
pared to low-burden TB settings (55% vs. 70%). Other
authors [10] performed a sub-analysis of paediatric studies
by definition of TB cases and reported lower pooled sensi-
tivity including clinical diagnoses TB cases vs. microbiologi-
cally confirmed TB cases (64% vs. 85% for QFT-G-IT, 66%
vs. 76% for T-SPOT.TB and 66% vs. 85% for TST) [10].
Our study is the first paediatric meta-analysis evaluat-
ing both QFT-G-IT and T-SPOT.TB performance by set-
ting. Moreover, we were first to present a sub-analysis of
studies performing a simultaneous three way comparison
Figure 6 Forest plot of sensitivity of tuberculin skin test (TST) in low-income countries. The squares are single study estimates and the
error bars represent the 95% confidence intervals (95% CIs). The diamonds are pooled estimates.
Figure 7 Forest plot of sensitivity of tuberculin skin test (TST) in high-income countries. The squares are single study estimates and the
error bars represent the 95% confidence intervals (95% CIs). The diamonds are pooled estimates.
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Table 2 Sensitivities and specificities of Interferon-gamma release assays (IGRAs) and tuberculin skin test (TST) in the present meta-analysis.
TST QFN-G-IT T-SPOT.TB
Sensitivity Low income countries 0.67 (95%CI 0.64-0.70);
Chi-square = 261.59; df = 15
(p =0.0000)
Inconsistency (I-square)= 94.3%
0.57 (95%CI 0.52-0.61); Chi-square = 51.04; df = 10 (p =0.0000)
Inconsistency (I-square)= 80.4%
0.61 (95%CI 0.57-0.65); Chi-square = 71.42;
df = 4 (p =0.0000)
Inconsistency (I-square)= 94.4%
High income countries 0.78 (95%CI 0.74-0.82);
Chi-square = 69.96; df = 17
(p =0.0000)
Inconsistency (I-square)= 79.3%
0.79 (95%CI 0.75-0.82); Chi-square = 77.27; df = 19 (p =0.0000)
Inconsistency (I2) = 75.4%
0.67 (95%CI 0.62-0.73); Chi-square = 44.79;
df = 8 (p =0.0000)
Inconsistency (I-square)= 82.1%
Including only studies using the
three assays simoultaneously
0.85 (95%CI 0.78-0.91);
Chi-square = 26.01; df = 5
(p =0.0001)
Inconsistency (I-square)= 80.8%
0.78 (95%CI 0.70-0.84); Chi-square = 16.85; df = 5 (p =0.0048)
Inconsistency (I-square)= 70.3%
0.76 (95%CI 0.68-0.83); Chi-square = 24.94;
df = 6 (p =0.0001)
Inconsistency (I-square)= 80.0%
Including microbiologically
confirmed cases (overall)
0.79 (95%CI 0.75-0.83);
Chi-square = 41.56; df = 16
(p =0.0005)
Inconsistency (I-square)= 61.5%
0.81 (95%CI 0.76-0.85); Chi-square = 45.51; df = 15 (p =0.0001)
Inconsistency (I-square)= 67.0%
0.80 (95%CI 0.73-0.86); Chi-square = 27.31;
df = 8 (p =0.0006)
Inconsistency (I-square)= 70.7%
Including microbiologically
confirmed cases, in low income
countries
0.74 (95%CI 0.68-0.80);
Chi-square = 20.28; df = 6
(p =0.0025)
Inconsistency (I-square)= 70.4%
0.66 (95%CI 0.55-0.76); Chi-square = 6.19; df = 4 (p =0.1857)
Inconsistency (I-square)= 35.3% - excluding studies with
immunocompromised children: 0.68 (95%IC 0.57-0.79); Chi-square =
3.18; df = 3 (p =0.3644)
Inconsistency (I-square)= 5.7%
0.80 (95%CI 0.59-0.90); Chi-square = 17.35;
df = 4 (p =0.0017)
Inconsistency (I-square)= 76.9%
Including microbiologically
confirmed cases, in high income
countries
0.86 (0.79-0.91); Chi-square =
14.06; df = 9 (p =0.1203)
Inconsistency (I-square)= 36.0%
0.86 (0.81-0.90); Chi-square = 25.78; df = 10 (p =0.0040)
Inconsistency (I-square)= 61.2%
0.79 (0.69-0.87); Chi-square = 9.90; df = 3
(p =0.0194)
Inconsistency (I-square)= 69.7%
Immunocompromised/HIV infected
children
0.54 (95%IC 0.49-0.59);
Chi-square = 71.45; df = 3 (p
=0.0000)
Inconsistency (I-square)= 95.8%
0.47 (95%CI 0.38-0.55); Chi-square = 37.77; df = 2 (p =0.0000)
Inconsistency (I-square)= 94.7%
Not evaluable
Specificity Low income countries 0.90 (95%IC 0.87-0.92); Chi-
square = 38.57; df = 7
(p =0.0000)
Inconsistency (I-square)= 81.9%
0.85 (95%CI 0.82-0.88); Chi-square = 19.15; df = 5 (p =0.0018)
Inconsistency (I-square)= 73.9%
0.93 (95%CI 0.87-0.96); Chi-square = 7.75;
df = 2 (p =0.0207)
Inconsistency (I-square)= 74.2%
High income countries 0.92 (95%CI 0.89-0.93);
Chi-square = 125.84; df = 10
(p =0.0000)
Inconsistency (I-square)= 92.8%
0.97 (95%CI 0.96-0.98); Chi-square = 38.83; df = 10 (p =0.0000)
Inconsistency (I-square)= 74.2%
0.98 (95%CI 0.96-0.99); Chi-square = 12.98;
df = 5 (p =0.0235)
Inconsistency (I-square)= 61.5%
Including only studies using the
three assays simoultaneously (all in
high income countries)
0.84 (95%CI 0.79-0.89);
Chi-square = 74.74; df = 4
(p =0.0000)
Inconsistency (I-square)= 94.6%
0.97 (95% CI 0.93-0.99); Chi-square = 6.05; df = 3 (p =0.1093)
Inconsistency (I-square)= 50.4%
0.97 (95%CI 0.93-0.99); Chi-square = 8.47; df
= 3 (p =0.0373)
Inconsistency (I-square)= 64.6%
Immunocompromised/HIV infected
children
0.97 (0.92-0.99); Chi-square =
0.95; df = 1 (p =0.0000)
Inconsistency (I-square)= 0.0%
Chi-square = 0.95; df = 1
(p =0.0000)
Inconsistency (I-square)= 0.0%
0.90 (95%CI 0.81-0.95); Chi-square = 0.00; df = 1 (p =0.9695)
Inconsistency (I-square)= 0.0% - only 2 studies could be included -
Not evaluable
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using all the tests in the same child, allowing to reduce
potential bias due to individual differences.
At a first glance, our meta-analytic results showed a
higher sensitivity of QFT-G-IT than TST in high income
countries (79% vs. 75%), where T-SPOT.TB seems to
have lower sensitivity than the two other tests (67%).
However this result was not confirmed including only
ascertained cases, with a microbiological confirmation. In
this sub-analysis T-SPOT.TB sensitivity reached 80%
(95%CI: 59-90) while QFT-G-IT sensitivity decreased,
but not significantly, to 66% (95%CI:55-76). This finding
suggests caution when interpreting results from studies
including probable and ascertained TB cases in children,
for possible misdiagnoses.
In a further sub-analysis including only studies perform-
ing simultaneously the 3 tests, all performed in high
income countries, overall including 618 children, no differ-
ent sensitivity of both IGRAs and TST was observed, while
a higher IGRAs specifity was confirmed (97% vs. 84%).
Very low sensitivity and specificity were found in the
sub-analysis performed with studies in immunocompro-
mised children. The meta-analytic estimate for sensitivity
was only 0.54 for TST, and 0.47 for QFT-G-IT, confirming
that IGRA results should be still interpreted with caution
in immunocompromised children.
Combining all these results, both IGRAs seem to be a
reasonable choice in the diagnosis of TB disease in immu-
nocompetent children aged > 5 years in high income
countries. In low income-countries and in immunocom-
promised children IGRAs’ performance is equivalent or
inferior to TST. Considerations regarding costs, availability
for clinicians and other health workers, patient acceptabil-
ity, ease of distribution and storage should also be taken
into account in this kind of setting. To date, data in the
paediatric population aged less than 5 years are limited,
and a specific sub-analysis for this category of studies
could not be performed as complete data were not evinci-
ble from the considered studies [19,28,30,42,59,60].
Conclusions
In conclusion IGRAs show good promise for improving
TB diagnosis only in immunocompetent children aged > 5
years in high income setting. Even in these subjects, how-
ever, IGRAs sensitivity was 67-86%, indicating that neither
test may rule out nor confirm the certainty of diagnosis
and, similarly to the TST, interpretation of results may be
difficult. As recently recommended by the NICE guide-
lines [13], paediatricians while deciding who deserves anti-
tubercular therapy, still have to consider clinical and
epidemiological data. Some authors suggest that the com-
bined use of TST and IGRAs might help clinicians by
increasing the diagnostic sensitivity to 90%, however inter-
pretation of discordant results is controversial [19].
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